Therapy-related acute promyelocytic leukemia (t-APL) is rare and often linked to previous treatment with alkylating agents or topoisomerase II inhibitors. This report describes three cases of t-APL ...

Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately detects the presence of ...

New technology that rapidly and simply detects disease-specific molecular alterations in two forms of leukemia could give ...

Blood cancer is not always fatal and advancements in treatment offer significant hope. Misconceptions exist, such as it being ...

Rapid blood cancer diagnostics enable faster decision-making, potentially saving lives by providing quicker, more accurate ...

Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.

BEIJING, Sept. 29 (Xinhua) -- The year 2024 is meant to be an important year for Chinese doctor Wang Zhenyi. Turning 100 this year, the celebrated medical scientist has been conferred the Medal of the ...

The Acute Promyelocytic Leukemia drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Promyelocytic Leukemia, complete with ...

维甲酸综合症（英语：retinoic acid syndrome,RAS）是“全反式维甲酸（all-trans-retinoicacid,ATRA）综合症”的简称，是使用维甲酸治疗急性早幼粒细胞白血病(Acute promyelocytic leukemia,APL）时发生的最严重并发症，多见于单用全反式维甲酸诱导治疗的过程中。 维基百科中的 ...

Although treatment of newly diagnosed APL with anthracycline-based chemotherapy combined with ATRA has been shown to be highly effective, limiting exposure to cytotoxic chemotherapy and ...